Day: 2025-08-29

RESULTS HIGHLIGHTS:- The Revenue for the six months ended 30 June 2025 (“the Period”) was approximately HK$1,834.8 million, representing an increase of approximately 7.8% as compared with the same period last year. The increase in the revenue was mainly due to the continued organic growth of the Group (mainly in Europe and Australia regions) and accelerated by our acquisition of Hexa Ceram Company Limited (“Hexa Ceram”), Thailand’s largest dental laboratory, which was completed in January 2025.- The Gross Profit Margin for the six months ended 30 June 2025 was approximately 54.8%; the gross profit was approximately HK$1,005.5 million, representing an increase of approximately 10.0% as compared with the same period last year.- The Group’s EBITDA for the six months ended 30 June 2025 was approximately HK$456.7 million, representing an increase of approximately 21.6% as compared with the same period last year.- The Group’s Net Profit for the six months ended 30 June 2025 was approximately HK$288.7 million, representing an increase of approximately 34.7% as compared with the same period last year.- Basic earnings per share for the six months ended 30 June 2025 amounted to HK30.37 cents.- The Board declared an interim dividend of HK10.7 cents per ordinary share for the six months ended 30 June 2025.- For the six months ended 30 June 2025, the Group’s digital solution cases (overseas and domestic) that are produced from its Mainland China, Thailand and Vietnam production facilities increased to approximately 457,653 cases, reflecting an increase of 24.4% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - 28 August, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, is pleased to announce the unaudited interim results for the six months ended 30 June 2025.During the six months ended 30 June 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. By leveraging on our sales and distribution network, we achieved a leading position in the dental prosthetics industry across Europe, North America, Greater China, Australia, and other countries.European BusinessesThe revenue generated from sales in the European markets accounted for the largest portion of our revenue for the period under review. During the period, the European market recorded a revenue of approximately HK$920.3 million, representing an increase of approximately HK$97.3 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 50.2% of the Group’s total revenue. The increase in revenue from the European market was attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the front runner providing comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed to and will continue to equip ourselves to provide the state-of-the-art digital solutions offering to the dental community in the market.North American BusinessesThe North American market represented the second largest portion of our revenue in the period under review. During the period, the North American market recorded a revenue of approximately HK$365.7 million, representing a decrease of approximately HK$19.6 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 19.9% of the Group’s total revenue.While demand for discretionary cosmetic treatments remained soft throughout the first half of 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers. Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties - an advantage that sets us apart from competitors. Although digitalization of imported product lines initially drove growth in mass-market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a subsequent decline in sales for our import-focused business unit.Greater China BusinessesDuring the period under review, the Greater China market recorded a revenue of approximately HK$293.2 million, representing a decrease of approximately HK$42.6 million as compared with six months ended 30 June 2024. This geographic market accounted for approximately 16.0% of the Group’s total revenue. The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesDuring the period under review, the Australian market recorded a revenue of approximately HK$137.9 million, representing an increase of approximately HK$10.0 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 7.5% of the Group’s total revenue. The double-digit increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 4.0% compared with the six months ended 30 June 2024.Other MarketsOther markets primarily include Indian Ocean countries, Malaysia, Taiwan, Singapore and Thailand. For the six months ended 30 June 2025, these markets recorded a revenue of approximately HK$117.8 million, representing an increase of approximately HK$87.9 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 6.4% of the Group’s total revenue. The increase in revenue from other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical challenges creating headwinds for businesses worldwide. However, the Group’s well-diversified global presence, spanning multiple regions and markets, positions it uniquely to navigate these challenges. Unlike competitors who operate in single countries or limited regions, the Group’s balanced and diversified country risk strategy ensures resilience and stability, even in turbulent times. This global footprint, combined with our ability to adapt to local market conditions, places the Group in the best position to outperform competitors and capitalize on emerging opportunities.Digitalization is an irreversible trend driving the consolidation of the dental prosthetics industry. The Group is taking full advantage of this trend, leveraging its centralized digital workflows, advanced production capabilities, and global network to enhance operational efficiencies and deliver superior customer experiences. Our continued investment in digitalization not only strengthens our competitive edge but also accelerates the consolidation of the industry, enabling the Group to capture a larger market share.Following our landmark acquisitions in previous years, including the recent acquisition of Hexa Ceram, Thailand’s largest dental laboratory, in January 2025, the Group’s global distribution and sales network is further diversified with a larger presence in Southeast Asia region. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides the Group with unparalleled flexibility to navigate challenges in connection with trade uncertainties and other geopolitical risks. With the Board’s extensive experience and determination to overcome short-term challenges, the Group is well-positioned to seize new business opportunities while remaining cautious and prudent in safeguarding shareholders’ interests.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 30,000 customers. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績摘要：- 截至2025年6月30日止六個月(「回顧期」)的收益約為18.3億港元，較去年同期增加約7.8%。收益增加主要由於本集團持續的自然增長(主要在歐洲及澳洲地區)，並藉著我們於2025年1月完成收購泰國最大的牙科實驗室Hexa Ceram Company Limited(「Hexa Ceram」)而加快。- 截至2025年6月30日止六個月的毛利率約為54.8%；毛利約為10.1億港元，較去年同期增加約10.0%。- 本集團於截至2025年6月30日止六個月的EBITDA約為4.6億港元，較去年同期增加約21.6%。- 本集團截至2025年6月30日止六個月的純利約為2.9億港元，較去年同期增加約34.7%。- 截至2025年6月30日止六個月的每股基本盈利為30.37港仙。- 董事會已宣派截至2025年6月30日止六個月的中期股息每股普通股10.7港仙。- 截至2025年6月30日止六個月，本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案(海外及國內)增加至約457,653件，較2024年同期增加24.4%，原因為客戶持續採用口腔內部掃描儀。香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 8月28日， 全球領先之義齒器材供應商-現代牙科集團有限公司（簡稱「現代牙科」或「本集團」，股份代號：03600.HK）欣然公佈截至2025年6月30日止6個月之未經審核中期業績。截至2025年6月30日止六個月，在牙科行業數碼化趨勢的持續支持下，本集團的多維度策略及持續提升的營運效率及生產力使其於本期間的收益、純利及EBITDA均創下紀錄。此情況在宏觀經濟環境充滿挑戰之時，包括牙科手術的需求普遍疲弱及貿易戰的不確定性下仍能體現。本集團充分善用位於泰國、越南及中國內地的全球化生產設施，積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動整合義齒行業，讓本集團進一步增加其於業內的市場份額。而我們數碼化的持續轉型有望改善顧客及患者的體驗，可令本集團在競爭對手中脫穎而出，表現優於同行。憑藉銷售及經銷網絡的優勢，我們於歐洲、北美、大中華、澳洲及其他國家的義齒行業均取得領先地位。歐洲市場業務自歐洲市場的銷售收益佔我們於回顧期間收益的最大部分。於回顧期間，歐洲市場錄得收益約9.2億港元，較截至2024年6月30日止六個月增加約9,734.1萬港元。此地理市場佔本集團收益總額約50.2%。歐洲市場收益增加是由於推出新產品(例如數碼化義齒)及我們最先進的數碼化流程，推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅，範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器，本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過建立以教育及數碼化為重點且貼近客戶需求的牙科解決方案生態系統，積極從國際及本地競爭對手取得市場份額；並透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己，為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務自北美市場的銷售收益佔回顧期間收益的第二大部分。於回顧期間，北美市場錄得收益約3.7億港元，較截至2024年6月30日止六個月減少約1,964.5萬港元。此地理市場佔本集團收益總額約19.9%。雖然2025年上半年對主動美容治療的需求仍然疲弱，我們的中央化數碼流程及廣泛的生產網絡讓我們為北美客戶提供更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地，在應對美國關稅的不確定性時帶來更大的彈性 - 使我們比其他競爭對手更具優勢。雖然進口產品線的數碼化起初帶動整體市場個案的增長，然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的後續銷售帶來下跌。大中華市場業務於回顧期間，大中華市場錄得收益約2.9億港元，較截至2024年6月30日止六個月減少約4,257.6萬港元。此地理市場佔本集團收益總額約16.0%。中國內地市場面對帶量採購政策及持續價格競爭的逆境。此亦導致中國內地診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意轉移低利潤業務，並專注於服務中及高價值客戶，確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀，特別是在政府最新的採購相關措施中，預計(i)規範義齒價格及建立價格透明度，促進公平競爭；(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量；及(iii)讓本集團從其規模化的生產團隊中得益及根據顧客或客戶更有效分配資源。澳洲市場業務於回顧期間，澳洲市場錄得收益約1.4億港元，較截至2024年6月30日止六個月增加約995.6萬港元。此地理市場佔本集團收益總額約7.5%。澳洲的收益錄得雙位數增長，反映牙科行業數化碼趨勢帶動更多新的數碼化產品，以及收購Digital Sleep的收益貢獻，但部分被相較於截至2024年6月30日止六個月，澳元兌港元貶值4.0%抵銷所致。其他市場其他市場主要包括印度洋國家、馬來西亞、台灣、新加坡及泰國。截至2025年6月30日止六個月，該等市場錄得收益約1.2億港元，較截至2024年6月30日止六個月增加約8,790.7萬港元。此地理市場佔本集團收益總額約6.4%。其他市場的收益增加主要由於新收購的Hexa Ceram的收益貢獻所致。展望及策略全球宏觀經濟環境仍然不明朗，地緣政治挑戰讓全球各行業處於逆境當中。然而，本集團的業務遍及全球多個地區及市場，多元化的經營使其在面對該等挑戰時享有獨特優勢。有別於在單一國家或有限地區經營的競爭對手，本集團均衡多元的國家風險策略，確保其在動盪時刻仍然堅毅不屈，平穩過渡。憑藉全球佈局及我們適應當地市場環境的能力，使本集團的表現優於競爭對手，並能把握新興機遇。數碼化勢不可擋，帶動義齒行業的整合。本集團於此趨勢中盡享優勢，憑藉其中央化數碼工作流程、先進的生產能力及全球化網絡，旨在提升營運效率及提供卓越的客戶體驗。我們持續對數碼化的投資不僅加強我們的競爭優勢，亦加快行業的整合，本集團可以從中獲得更大的市場份額。我們在過往多年作出多項標誌性收購，包括最近於2025年1月收購泰國最大牙科實驗室Hexa Ceram，本集團的全球分銷及銷售網絡進一步多元化，加強在東南亞地區的影響力。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地，讓本集團在應對與貿易不明朗因素及其他地緣政治風險等相關的挑戰時帶來更高彈性。憑藉董事會豐富的經驗及克服短期挑戰的決心，本集團已準備就緒，繼續全力把握新商機，同時保持審慎及謹慎的態度，以保障股東利益。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問，專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材，例如牙冠及牙橋；活動義齒器材，例如活動義齒；及其他器材，例如正畸類器材、透明牙套、運動防護器及防鼾器。現代牙科集團擁有多個備受稱許的全球品牌，包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及紐西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務，令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 30,000 名客戶。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Everbright Limited ("CEL" or "the Company", stock code: 165.HK) announced its Interim results for the six months ended 30 June 2025 ("the reporting period").Highlights of the 2025 Interim Results- Strong Growth: Total income reached HK$2,068 million, representing a significant increase compared with the same period last year;- Turning Around from Loss to Profit: During the reporting period, the Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company was HK$399 million, successfully turning around from a net loss;- Fundraising Increase: The total assets under management (AUM) of CEL's funds amounted to approximately HK$119.4 billion, with new fundraising amounting to approximately HK$2,741 million;- Successful Exits: The total exits from funds and principal investments amounted to HK$2.018 billionï¼›with a MOIC (multiple on invested capital) of approximately 2.78 times;- Cost Control and Efficiency Enhancement: Enhanced lean management led to a 10% year-on-year decrease in operating costs and a 38% year-on-year reduction in finance costs;- Adequate Liquidity: The Company had cash and cash equivalents of approximately HK$8.1 billion;- Steady Dividend: An interim dividend of HK$0.05 per share for 2025.In the first half of 2025, China's private equity industry entered a more stable stage of development. Leveraging its strengths as patient capital, CEL maintained strategic focus, seized market opportunities with precision, and promptly adjusted its fundraising, investment, management, and exit strategies. By consolidating its core businesses, gradually unlocking value potential, and significantly improving overall operational efficiency, the Company achieved a strong rebound in performance.During the reporting period, CEL realised total income of HK$2,068 million, representing a significant increase of HK$2,182 million from the same period last year. This was mainly due to a significant increase in investment income, which fully demonstrated the Company's sound investment vision and solid foundation in long-term investing. The Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company amounted to HK$399 million, successfully turning around from a net loss attributable to shareholders of HK$1,282 million in the same period last year, representing a significant improvement in performance.Meanwhile, the Company continued to strengthen its refined management, sustaining healthy and steady business development. During the reporting period, operating costs represented a year-on-year decrease of 10%, with proactive leverage reduction measures implemented. The gearing ratio decreased by 2% compared with the end of 2024, while finance costs fell 38% year-on-year, demonstrating significant results in cost control and efficiency improvement. As at the end of June 2025, the Company had cash and cash equivalents of approximately HK$8.1 billion, representing sufficient liquidity.By concentrating its resources and business focus on high-potential products, the Company further reinforced its core business. During the reporting period, with new fundraising amounting to approximately HK$2,741 million, the total AUM of CEL’s funds amounted to approximately HK$119.4 billion, managing 72 fund products and covering primary market funds, secondary market funds, and fund of funds. During the reporting period, the Company invested in a total of 9 projects and exited, fully or partially, from 46 project.Following the practice of sharing the Company's operating results with shareholders, the Board declared interim dividend of HK$0.05 per share for 2025 (2024 interim dividend: HK$0.05 per share).Business Highlights in the First Half of 2025Firstly, CEL Harnessed the Strengths of Group-Based Operations to Enhance Fundraising SynergyIn the first half of 2025, the Company successfully launched the Huaian Hongze Guangqi Fund and the Xiamen Marine High-Tech Industrial Development Fund, with a total scale of RMB2.5 billion. The Huaian Fund targets growth-stage projects in the areas of new energy, new materials, and intelligent manufacturing, with its first round of capital contribution completed in the first half of the year. The Xiamen Marine Fund is dedicated to incubating and transforming scientific and technological innovations in the marine sector, driving the high-quality development of the marine economy. At the same time, several other funds have been approved and are progressing smoothly, following the established plan.Secondly, CEL Strengthened Core Businesses to Drive Robust Recovery in PerformanceDuring the reporting period, the Company total exits from funds and principal investments amounted to HK$2.018 billion. This include the full exit from Xpeng Motors, DAPU Telecom, and Taboola, alongside partial exit from iSoftStone, Dekon Food and Agriculture, 4Paradigm, and other projects. With a MOIC (multiple on invested capital) of approximately 2.78 times, these exits significantly boosted the DPI of multiple funds, generating substantial returns for LPs. Several listed projects, including Circle, Dekon Food and Agriculture, and NetEase Cloud Music, delivered strong market performance in the first half of the year, making notable contribution to the Company's investment returns. In the first half of the year, secondary market funds expertly capitalised on structural opportunities, achieving impressive investment performance. Notably, the Everbright Convertible Bond Opportunity Fund ranked second among similar funds in Barclays' performance rankings.Thirdly, CEL Anchored Strategy Around Scientific and Technological Innovation, With a Particular Focus on Key Industry SectorsGuided by deep industrial insight and a forward-looking strategic vision, the Company accelerated its investment activity in the first half of the year. It targeted emerging strategic industries such as artificial intelligence, chips and semiconductors, and biomedicine, with a total investment of approximately HK$264 million by funds. We have nurtured and supported a number of technology leaders, including Yangtze Memory and Wuhan Xinxin (both prominent domestic memory chip producers), HengYi Biotech (a company engaged in the research and development of innovative drug for tumors and autoimmune diseases), J-Sensor (astrategic supplier of domestic industrial automation modules and core sensors for new energy vehicles), and Tec-Do (a service provider in the field of big data and BI), among others. These investments reflect our commitment to strengthening China’s science and technology enterprises. Meanwhile, CEL supported excellent sub-funds such as Jinyi Capital and Eastern Bell Capital through its FoF platforms. These FoF investments allow us to fully leverage the advantages of resource amplification, risk diversification, and diversified returns.Fourthly, CEL Optimise Business Management to Unlock Growth MomentumIn the first half of the year, the Company continued to optimise its financing structure and took full advantage of the domestic interest rate cut cycle, issuing RMB3 billion in the first tranche of its 2025 medium-term notes at a coupon rate of 2.09% per annum — the lowest coupon rate in the Company's bond issuance history. During the reporting period, the Company's overall financing cost declined by 133 basis points year-on-year to 3.14%, while its finance costs reduced by 38% year-on-year. Operating costs also recorded year-on-year decrease of 10%, underscoring the solid progress made in reducing costs and increasing efficiency. The Company continued to optimise its risk management framework. CEL advanced the classification of risk assets, reinforced dynamic valuation management, and established a risk monitoring and early warning system, thereby improving the effectiveness of risk prevention and control across the full business cycle.Fifthly, CLE Enhanced Public Services and Upgraded Commercial Consumption.CEL leveraged its industrial strengths to enhance the quality of its products and services, catering to the growing demand for consumer services among citizens. In the commercial consumption arena, EBA successfully launched 18 "IMIX Park" shopping centres across nine cities nationwide,managing approximately 2.6 million square metres in total. These centres created approximately 37,700 jobs, attracted approximately 121 million customer visits, and hosted more than 4,500 tenant merchants in the first half of 2025. During the reporting period, Phase I of the "Zhongguancun ART PARK IMIX Parks", a flagship consumption infrastructure and urban renewal project in Beijing, opened smoothly, significantly upgrading the consumer experience and giving a strong boost to domestic demand.Sixthly, Key Portfolio Companies Maintain Stable Growth with Strong ResilienceThe core business of China Aircraft Leasing Group Holdings Limited (CALC) progressed steadily with remarkable improvements in operating quality and efficiency. The net profit attributable to shareholders recorded a year-on-year increase. As of June 30, 2025, CALC’s fleet reached 181 aircraft, leased to 41 airlines across 22 countries and regions. Everbright Senior Healthcare has been seizing the development opportunities in China's healthcare industry. As of 30 June 2025, Everbright Senior Healthcare has 237 institutions of various types in 49 cities across the country, it managed more than 30,000 beds, with occupancy rates increasing by 1.77%. Meanwhile, Terminus continued to deepen the integration of AI technology across multiple industries, driving intelligent transformation and implementing localised AI applications and digital-intelligent solutions, while receiving multiple authoritative certifications.Seventhly, CEL Strengthened ESG Framework to Promote Sustainable DevelopmentDuring the reporting period, CEL continued to promote the construction of its ESG system. the Company maintained an "A" rating in the MSCI ESG Rating and received the "BEST ESG (S)" award from the Hong Kong Investor Relations Association (HKIRA). The Company earnestly fulfilled its role as a corporate citizen by leveraging its own capabilities, organizing and participating in 46 cultural and social welfare activities in the first half of the year, serving over ten thousand people, and upholding high standards in discharging its social responsibilities.In the first half of 2025, under the strong leadership of the Everbright Group, the guidance of the Board of Directors, and the collective efforts of all employees, the Company achieved significant improvements in operational efficiency and quality, with new drivers of growth continuing to strengthen, resulting in hard-won achievements. As China's economy continues to improve and policy support intensifies, the Chinese private equity industry will embark on a new journey of high-quality development. CEL will seize market opportunities, capitalise on the momentum, and lay a solid foundation for a strong start to the 15th Five-Year Plan. In the second half of the year, CEL will continue to adhere to the overall principle of seeking progress while maintaining stability, continue to focus on revenue growth and cost control, optimise operational management, seize opportunities in key business areas such as fundraising, investment, management, and exit, leverage the cross-border platform and the synergistic advantages of the group, cultivate long-term patient capital, and advance the "five major financial initiatives", through scientific strategic planning, professional investment teams, and rigorous risk management, and continuously create value for shareholders.China Everbright Limited, https://www.everbright.com/en [SHSE:601818][HKEX:00165][OTCPK:CEVIF][OTCPK:CEVIY] Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025年中期業績表現要點：- 強勁增長：收入總額為港幣20.68億元，較去年同期大幅增長；- 扭虧為盈：報告期內，公司盈利港幣6.50億元，其中歸屬于本公司股東之盈利為港幣3.99億元，實現扭虧為盈；- 募資提升：旗下基金資產管理總規模（AUM）約港幣1,194億元，期內新增募資約港幣27.41億元；- 退出良好：基金及自有資金層面合計退出金額港幣20.18億元，退出回報倍數（MOIC）約2.78倍；- 控本增效：強化精益管理，經營成本同比下降10%，財務費用同比下降38%；- 流動性充裕：擁有現金及現金等價物約港幣81億元；- 穩健派息：中期股息為每股港幣0.05元。香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) - 中國光大控股有限公司（「光大控股」，股份代號：165.HK）公佈截至2025年6月30日止6個月（「報告期」）之中期業績。2025年上半年，中國私募股權行業逐步邁入更加穩健的發展階段。光大控股充分發揮耐心資本優勢，保持戰略定力，準確把握市場機遇，及時調整募投管退策略，夯實核心主業，價值潛能逐步釋放，公司整體經營質效大幅改善，業績強勁復蘇。報告期內，光大控股實現收入總額為港幣20.68億元，較去年同期大幅增長港幣21.82億元，主要得益於投資收入的大幅增加，充分展現了公司良好的投資眼光和長期投資底蘊。公司盈利港幣6.50億元，其中歸屬于本公司股東之盈利為港幣3.99億元，較去年同期淨虧損港幣12.82億元成功實現扭虧為盈，業績顯著改善。與此同時，公司繼續強化精細管理，保持健康穩健的經營發展。期內，經營成本同比下降10%，主動壓減槓桿，計息負債比率對比2024年末減少2%，控本增效成果顯著，財務費用同比下降38%。公司流動性保持充裕，截至2025年6月底，擁有現金及現金等價物約港幣81億元。公司資源和業務重心繼續向優勢產品聚焦，進一步穩固核心主業。報告期內，新增募資約港幣27.41億元，旗下基金資產管理總規模（AUM）約港幣1,194億元，在管基金產品72只，涵蓋一級市場基金、二級市場基金和母基金。期內，共計對9個項目進行投資，完全/部分退出項目46個。秉承與股東分享經營成果的發展理念，董事會宣派2025年中期股息為每股港幣0.05元（2024年中期股息：每股港幣0.05元）。2025年上半年經營要點一、發揮集團化運營優勢，加強募資協同體系2025年上半年，公司新完成設立淮安洪澤光啟基金和廈門海洋高新產業發展基金，總規模為人民幣25億元。淮安基金關注成長階段的新能源、新材料和智能製造等項目，上半年已完成首期實繳到位；廈門海洋基金關注海洋科技成果孵化轉化，助力海洋經濟高質量發展。同時，多只基金已完成立項，目前正按照既定規劃有序推進中。二、穩固核心主營業務，驅動業績強勁復甦報告期內，公司基金及自有資金層面合計退出金額港幣20.18億元，完成小鵬汽車、大普通信、Taboola三筆完全退出，部分退出了軟通動力、德康農牧、第四範式等多個項目，退出回報倍數（MOIC）約2.78倍，全面帶動多只基金DPI提升，為基金LP帶來了可觀收益。Circle、德康農牧、網易雲音樂等已上市項目在上半年均有良好的市場表現，為公司貢獻較好的投資收益。二級市場基金上半年精准把握結構性機會，投資業績表現較好，其中光大可轉債機會基金榮獲巴克萊評選的同類基金業績排名的第二名。三、錨定科技創新戰略，佈局重點行業領域公司基於深刻的產業洞察和前瞻性的戰略視野，在上半年加快投資節奏，重點聚焦人工智慧、芯片半導體、生物醫藥等戰略性新興產業，基金層面合計投資約港幣2.64億元。培育並支持多家科技領軍企業，包括長江存儲和武漢新芯（國產存儲芯片巨頭）、恒翼生物（腫瘤及自免創新藥研發企業）、鈞嵌傳感（國產工業自動化模組及新能源車核心感測器戰略供應商）、鈦動科技（大數據與BI領域服務商）等，支援中國科創企業做優做強。同時通過母基金支持金鎰資本、鐘鼎資本等優秀的子基金，發揮母基金資源放大、風險分散、收益多元的優勢。四、優化經營管理，釋放發展新動能公司持續優化融資結構，上半年把握國內降息週期，發行人民幣30億元的2025年第一期中期票據，年利率2.09%，創公司歷史債券發行票面利率新低。報告期內，公司整體融資成本同比下降 133個基點至 3.14%，財務費用同比下降 38%，經營成本同比下降10%，降本增效成果顯著。公司持續優化風險管理體系，通過推進風險資產分級分類、強化動態估值管理及構建風險監測預警機制，實現全流程風險防控效能提升。五、強化民生服務，商業消費更新升級光大控股發揮旗下產業優勢，提升產品服務品質，以滿足居民日益增長的消費服務需求。商業消費方面，旗下光大安石已在全國9個城市成功打造18座"大融城"購物中心，管理規模約260萬平方米，創造了約3.77萬個工作崗位，2025年上半年累計服務消費者約1.21億人次，服務商戶超過4500個。報告期內，北京重點消費類基礎設施及城市更新項目「中關村ART PARK大融城」一期順利開業，有效帶動消費體驗升級，擴大內需。六、重要投資企業穩中向好，韌性強勁中飛租賃主業發展穩健，經營質量和運營效率持續提升，股東應占淨利潤同比增長。截至2025年6月30日，中飛租賃機隊規模達181架，租賃予22個國家及地區的41家航空公司。光大養老緊抓國內康養產業發展機遇，在全國49個城市擁有各類養老機構數量237個，提供養老床位3萬余張，入住率提高1.77%。特斯聯持續深化AI技術與多產業融合，驅動多行業智慧化升級，落地國產化AI應用與數智方案，並榮獲多項權威認證。七、強化構建ESG體系，推動可持續發展報告期內，公司持續推動ESG體系建設，公司MSCI（明晟）ESG評級維持為A級，並獲得香港投資者關係協會（HKIRA）頒發的「BEST ESG（S）」獎項。公司切實發揮自身所能，履行企業公民責任擔當，上半年共組織及參與各類文化和社會公益活動46次，服務人群超過萬人，高標準履行社會責任。 2025年上半年，在光大集團的堅強領導、董事會的帶領和全體員工的共同努力下，公司經營質效全面改善，發展新動能持續增強，取得來之不易的成績。隨著中國經濟的持續向好，政策支持力度的不斷加強，中國私募股權行業將邁入高質量發展的新征程。光大控股將緊抓市場機遇，乘勢而上，為實現"十五五"良好開局夯基固本。下半年，光大控股將繼續堅持穩中求進的工作總基調，持續做好增收控本，優化經營管理，搶抓"募投管退"等關鍵業務環節的機遇，借助跨境平台和集團綜合協同的勢能，培育長期耐心資本，做好金融「五篇大文章」，通過科學的戰略規劃、專業的投資團隊和嚴格的風險管理，持續為股東創造價值。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com